TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Two reviews found no clearly detectable increase in most measured pregnancy complications or congenital anomalies after GLP-1 drug exposure around conception or early pregnancy. The researchers stressed that limited evidence does not establish safety, and current advice to stop treatment before conception remains in place.
Two reviews of pregnancy data found no clearly detectable increase in most measured adverse outcomes among women exposed to GLP-1 receptor agonists around conception or early pregnancy, but the researchers said the findings do not establish that the drugs are safe during pregnancy. The results may offer limited reassurance after inadvertent exposure, while current recommendations to stop treatment before planned conception remain unchanged.
A systematic review and meta-analysis of 10 studies covering more than 2.1 million pregnancies found no clear increase in miscarriage or intrauterine death, congenital anomalies, preterm birth, hypertensive disorders, gestational diabetes, or several measures of fetal size and gestational weight gain among women exposed during the periconceptional period. The analysis compared pooled estimates for exposed and unexposed pregnancies.
The review did report a lower pooled estimate for preeclampsia among exposed women: odds ratio 0.87, with a 95% confidence interval of 0.78 to 0.98. The finding came from only two datasets, and Asma Khalil, MD, MSc, of City St George’s University of London, and colleagues said it should be interpreted cautiously. The authors also cited varied definitions of exposure, possible residual confounding and small numbers of studies for some outcomes.
A second review, presented at the European Association for the Study of Diabetes annual meeting and published in Lancet Obstetrics, Gynaecology, & Women’s Health, included data on more than 40,000 women, primarily with type 2 diabetes. Across four studies, it found no increase in congenital anomaly risk when GLP-1 drugs were discontinued during the first trimester (risk ratio 1.02; 95% CI 0.96-1.08). Early pregnancy loss was more common in exposed women in two studies (RR 1.31; 95% CI 1.26-1.35), but the largest contributing study combined miscarriage with termination, complicating interpretation.
Pregnancy Decisions Under Limited Evidence
GLP-1 medicines are used for conditions including type 2 diabetes and obesity, and their use has grown as the drug class has expanded in popularity and indications. The reviews assessed pregnancy outcomes following exposure around conception and early pregnancy. They provide data on observed outcomes but cannot determine whether continuing treatment during pregnancy is safe.
The absence of a detectable increase in these studies does not establish that there is no risk. The authors of the larger review said the results may provide limited reassurance after inadvertent exposure before conception or in early pregnancy, but should not be treated as support for ongoing treatment. Drug labeling does not approve GLP-1 receptor agonists for use during pregnancy and recommends stopping them at least two months before planned conception; the source report notes that this interval is based on limited human data.
Tricia Tan, MBChB, PhD, of Imperial College London, said the studies found no detectable serious problem across pregnancy outcomes. She cautioned that research based on past practice may not reflect current practice. The reviews provide information about exposure while leaving safety questions unresolved.
What the Reviews Examined
The first analysis pooled observational studies of women who used GLP-1 drugs in the period around conception and compared their pregnancy outcomes with those of women who did not use them. Its authors found that subgroup analyses by reason for treatment were consistent with the main analysis. Such consistency does not remove the limits of the underlying studies, including differences in how drug exposure was defined.
The second review focused largely on women with type 2 diabetes and included outcomes after drugs were discontinued during the first trimester. Alongside the analysis, Claire Meek, PhD, of the University of Leicester, and colleagues developed an international consensus statement on GLP-1 use before, during and after pregnancy in women with diabetes. The statement addresses clinical targets and ways to help women understand when and how to stop treatment safely.
Meek said contraception remains strongly recommended while taking GLP-1 drugs, and treatment should stop in early pregnancy if conception occurs. She also said there is substantial interest in use among women with type 1 diabetes but almost no evidence. The consensus authors discussed possible roles before conception and after birth for gestational diabetes, while noting that direct evidence is lacking and data on lactation remain scarce.
“The findings “may provide limited reassurance following inadvertent exposure before conception or during early pregnancy, but they should not be interpreted as supporting continued treatment during pregnancy.””
— Asma Khalil, MD, MSc, and colleagues
Safety Questions Still Open
The reviews cannot establish whether GLP-1 medicines are safe during pregnancy. Their findings rely on a limited set of studies, and the first analysis identified exposure-definition differences and residual confounding as constraints. Several outcomes were informed by only a small number of studies, leaving estimates less certain.
The second analysis’s early-loss result also requires care: miscarriage and termination were combined in the largest contributing study, so the reported increase cannot be interpreted as a miscarriage estimate alone. The source report does not provide enough detail to determine how the results apply across specific GLP-1 drugs, doses or patterns of use. Evidence for women with type 1 diabetes and for use during breastfeeding is particularly scarce.
More Research and Clinical Guidance
The authors said current recommendations to discontinue GLP-1 receptor agonists before conception should remain unchanged until more robust evidence is available. For patients who become pregnant while taking a GLP-1 drug, Meek’s guidance is to stop treatment in early pregnancy; decisions about care should be discussed with a qualified clinician.
The consensus statement calls for clearer strategies to help women plan when to stop treatment and how to do so safely. Its authors also urged greater investment in women’s health research, regulatory changes that allow evidence generation while protecting patients, and mandatory reporting of sex-disaggregated data. How quickly those changes will occur, and when stronger pregnancy safety data may become available, remain unclear.
Key Questions
Do the reviews show that GLP-1 drugs are safe during pregnancy?
No. They found no clear increase in most measured outcomes, but the researchers said the evidence does not establish safety during pregnancy.
What should someone do after becoming pregnant while taking a GLP-1 drug?
Meek said treatment should stop in early pregnancy. A patient should discuss the situation and next steps with a qualified clinician.
How long before planned conception does labeling recommend stopping these drugs?
The source report says drug labeling recommends stopping GLP-1 receptor agonists at least two months before planned conception. It notes that this guidance relies on limited human data.
What did the second review find about early pregnancy loss?
It reported a higher pooled estimate among exposed women across two studies (RR 1.31; 95% CI 1.26-1.35). Interpretation is limited because the largest contributing study combined miscarriage and termination.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
